Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026
Rhea-AI Summary
Exagen (Nasdaq: XGN) will release financial results for the quarter ended March 31, 2026, before the market opens on May 11, 2026.
John Aballi, President and CEO, and Jeff Black, CFO, will host a conference call and webcast at 8:30 a.m. ET (5:30 a.m. PT) that day. Webcast and replay will be available via the Exagen Investor Relations website; telephone replay available through May 25, 2026.
Positive
- None.
Negative
- None.
News Market Reaction – XGN
In the Apr 27 session, XGN gained 1.48%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 24 | Earnings date notice | Neutral | -0.3% | Announced timing and access details for Q4 and full-year 2025 results. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings-date announcements have caused only modest share moves, with the last similar event seeing about a -0.27% reaction.
Recent news has highlighted improving fundamentals at Exagen, including record 2025 revenue of $66.6M, higher AVISE CTD volumes, and detailed guidance for 2026. The company also regularly pre-announces timing for earnings releases, as seen on Feb 24, 2026. Today’s earnings-date notice continues that communication pattern, setting expectations for the upcoming Q1 2026 report without adding new financial metrics.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARLSBAD, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended March 31, 2026, before the market opens on Monday, May 11, 2026. John Aballi, President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call at 8:30 a.m. ET (5:30 a.m. PT) that morning to review the Company’s results.
Conference Call & Webcast:
- U.S. dial-in: 877-407-0890
- International dial-in: +1 201-389-0918
- Webcast: Available via the Exagen Investor Relations website at investors.exagen.com
Replay: A telephone replay will be available until Monday, May 25, 2026:
- U.S. replay: 877-660-6853
- International replay: +1 201-612-7415
- Replay passcode: 13759736
- Webcast: A recording of the webcast will be available one hour after the call concludes via the Exagen Investor Relations website at investors.exagen.com
About Exagen Inc.
Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision-making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s disease earlier and with greater accuracy. Exagen’s CLIA-certified, CAP-accredited laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.
For more information, visit Exagen.com or follow Exagen on LinkedIn.
Contact
Tina Jacobsen, CFA
Exagen Inc.
ir@exagen.com
